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Unrecognized or silent myocardial ischaemia during daily life has generated considerable recent interest as it occurs in all
forms of coronary artery disease, ranging from those who are totally asymptomatic to those who have had a myocardial
infarction. A characteristic diurnal cycle of both frequency and duration of these ischaemic episodes occurs and is the same
as the diurnal variation observed in frequency of acute myocardial infarction and out-of-hospital sudden death. These
findings suggest common underlying triggering mechanisms which may couple transient ischaemia to these morbid events.
The presence of daily-life silent ischaemia is associated with a two- to five-fold increase in risk of death and similar increases
in risk of non-fatal infarction. Multivariate analysis suggests that silent ischaemia is the best independent predictor of
outcome (e.g. death, or myocardial infarction) among a number of factors that include coronary angiography and exercise
test results.
Anti-anginal agents (e.g. nitrates, (i-blockers, calcium antagonists) also reduce or prevent daily-life silent ischaemia.
While anti-anginal treatment can control both symptomatic and silent ischaemic episodes, therapy directed towards
symptom control alone may be insufficient to control recurrent silent ischaemia in many individuals. A recent report
suggests that suppression of painless ischaemia by anti-ischaemic treatment is associated with a reduced risk of adverse
outcome.
Additional advances in this area will require the results of large, well-controlled multicentre clinical trials, several of
which are currently in progress. We anxiously await the results of these important trials: the Total Ischaemic Burden
European Trial (TIBET), the Atenolol Silent Ischaemia Trial (ASIST) and the Asymptomatic Cardiac Ischaemia Pilot
(ACIP).
Introduction
The topic of silent myocardial ischaemia has received con-
siderable attention over the past few years for a number of
reasons including its high prevalence rate, association
with adverse outcome, and controversy about whether or
not it should be treated. The purpose of this paper is to
place silent ischaemia in perspective relative to its medical
treatment. Terminology and pathophysiology will be
addressed, as well as pathophysiological mechanisms.
Discussion of the latter might help in the selection of a
rational approach to pharmacological management of
this syndrome, and the relative merits of /?-blockers vs
calcium antagonists are considered.
TERMINOLOGY
Silent ischaemia may mean different things to different
people. Silent ischaemia has been used to describe the
totally asymptomatic individual with coronary artery dis-
ease (CAD); this could be the patient who has never had
symptoms, or the patient who is asymptomatic after myo-
cardial infarction, but has an abnormal exercise ECG or
thallium test indicative of transient ischaemia (Table 1).
The term is also used when referring to transient asympto-
matic left ventricular dysfunction, identified by wall
motion abnormalities detected during non-invasive or
invasive imaging. Silent ischaemia may also be used to
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Table I Silent myocardial ischaemia terminology
Asymptomatic coronary artery disease
Latent coronary artery disease




left ventricular wall motion abnormalities
myocardial metabolic abnormalities
describe the asymptomatic patient with severe coronary
artery obstruction at angiography or at post-mortem. The
patient who has suffered a silent or unrecognized myocar-
dial infarction is also said to have had silent ischaemia.
More commonly silent ischaemia is used to describe the
patient with known CAD, with or without symptoms,
who also has transient asymptomatic ischaemic type ST
segment depression discovered during continuously
recorded ECG (either in hospital, usually in the cardiac
care unit or during daily life by ambulatory ECG record-
ing). This paper focuses specifically on patients with
'daily-life ischaemia'. Daily-life ischaemia is defined as a
period when ischaemic-type ST segment changes occur
during the activities of daily life, between 70% and 90% of
which are not accompanied by recognizable symptoms.
The term daily-life ischaemia is preferable to silent
ischaemia, as it avoids confusion with the other situation-
soutlined above and correctly describes a situation that
also includes a few symptomatic ischaemic episodes.
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Table 2 Considerations to justify treatment of patients with daily-life
ischaemia
Proven
Independent risk factor for adverse outcome
Treatment prevents or reduces daily-life ischaemia
Under investigation
Treatment prevents or reduces adverse outcome
Prevention or reduction of ischaemia is associated with
reduced risk for adverse outcome compared with those
in whom treatment fails to prevent or reduce ischaemia
Reduction in adverse outcome afforded by treatment is
cost-effective
WHAT IS THE RATIONALE FOR TREATMENT?
A number of issues provide partial justification for
treatment of the largely asymptomatic problem of daily-
life ischaemia (Table 2). Daily-life ischaemia is an inde-
pendent risk factor for adverse outcome of CAD; over
1200 patients studied by ambulatory ECG monitoring
and followed for months or years have yielded sufficient
data to support this'12'. Pharmacological treatment can
prevent or reduce daily-life ischaemia; numerous studies
(some of which are reviewed in this paper) provide sup-
porting evidence for this. Other issues also important in
the justification of treatment of daily-life ischaemia are
under investigation. These include questions such as
whether the treatment of patients with daily-life ischaemia
reduces adverse outcome, or whether prevention or reduc-
tion of daily-life ischaemia is associated with a reduced
risk for adverse outcome compared with situations where
treatment fails to prevent or reduce ischaemia. Finally, it
remains to be proved that reduction in adverse outcome in
patients, who are not necessarily severely symptomatic, is
afforded by a detection strategy and treatment that is
cost-effective. When all of these considerations are satis-
factorily addressed, treatment of daily-life ischaemia may
be justified.
Is daily-life ischaemia a risk factor for adverse outcome?
The studies that deal with daily-life ischaemia and risk
of cardiovascular events in patients with stable angina or
stable CAD have been reviewed in detail elsewhere'2'.
More than 600 patients with stable angina have been
studied; the risk ratios for death and adverse outcome
(death or non-fatal infarction) are markedly increased in
the presence of daily-life ischaemia. In some reports, the
risk ratios are approximately four or higher for death or
adverse outcome'3"9'; the risk ratio for adverse outcome in
a study by Rocco et alP\ for example, reached approxi-
mately 14. Data from over 500 patients with unstable
angina'10"15', and over 200 post-myocardial infarction
patients have also been reported'1617'. All of these patient
subsets behave similarly with respect to the additional
importance of daily-life ischaemia, except that the risk
ratios for adverse outcome appear somewhat higher for
unstable angina and postinfarction patients than for
patients with stable CAD syndromes. Several studies also
used multivariate analysis and concluded that daily-life
ischaemia was the most important independent predictor
of adverse outcome'5918'.
Thus, there are ample data to conclude that daily-life
ischaemia is an independent risk factor for adverse
outcome in these patient populations.
Does anti-anginal therapy control daily-life ischaemia?
Does anti-anginal therapy in the usual clinical setting
also control daily-life ischaemia? Mulcahy and co-
workers'19' reported that in 114 patients with stable
angina pectoris who were receiving what was thought to
be clinically optimal anti-anginal therapy, about one-
third continued to have ischaemic episodes during daily
monitoring. Data from other studies support this con-
clusion, and suggest that about 40% of patients who are
thought to be effectively treated for suppression of angina,
continue to have daily-life ischaemia191. Deedwania and
colleagues'9' found that treated patients who continued to
have daily-life ischaemia had reduced survival compared
with those who did not. Recently, Yeung and co-
workers'20'confirmed this suggestion. It can be concluded,
therefore, that symptom-titrated anti-anginal therapy
does not prevent daily-life ischaemia in a significant
minority of patients.
Pathophysiological clues to appropriate pharmacotherapy
Some suggest that most silent ischaemia is not necess-
arily due to physical activity and that environmental and
mental stress may play an important role'21-22'. These con-
clusions were based on detailed diary analysis. Others
found that the heart rate at onset of most daily-life ischae-
mia was lower than the heart rate observed in the same
patients at onset of ischaemia induced in the treadmill
laboratory. In another study, ambulatory monitoring
over 3 consecutive days'21' showed that both heart rate and
ischaemic activity oscillate in diurnal patterns character-
istic of the patterns for both myocardial infarction and
out-of-hospital sudden death (Fig. 1). Heart rate begins to
increase shortly after waking, is fastest about noon, and is
slowest during sleep. Ischaemic activity occurs frequently
during periods when the heart rate is increased, and infre-
quently when the heart rate is slowed, /^-blockade elimi-
nates the oscillations in heart rate and markedly reduces
ischaemic activity. In addition, the residual ischaemic
activity that occurs during /?,-adrenergic blockade does
not have a circadian pattern. These observations suggest
that ischaemic activity occurring during daily life is very
closely coupled to the oscillations in heart rate that occur
during the day, and that this diurnal variation in heart
rate is mediated, in part, by /?,-adrenergic activation.
Recently, Deedwania and Nelson'24' recorded the ambu-
latory ECG and ambulatory blood pressure throughout a
24-hour period in a group of CAD patients (Fig. 2). Heart
rate and ischaemia patterns were similar to those described
by other laboratories'23'. Increases in heart rate, systolic
blood pressure and ischaemic activity occur in the early
morninghoursshortly after the patient wakesand becomes
active. Although not measured directly, contractility
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Figure 2 Circadian pattern of transient ischaemic episodes, heart rate, systolic
blood pressure and double product. From Deedwania and Nelson'24'.
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probably also increases during these hoursof/?,-adrenergic
activation. It seems reasonable to conclude that increases
in myocardial oxygen demand are, at least in part, respon-
sible for ischaemic episodes that occur during daily life, but
as neither the heart rate nor blood pressure increases
recorded during daily life reach the levels achieved at the
onset of ischaemia during treadmill exercise, other factors
must also be involved. These include an increase in myo-
cardial oxygen demand which is not reflected in the heart
rate and systolic blood pressure, or in a reduction in myo-
cardial oxygen delivery. Recent evidence indicates that cold
exposure and mental stress (which are known to increase
indices of myocardial oxygen demand) also provoke
coronary artery constriction at sites of endothelial dys-
function'25-26'. This suggests that environmental stresses
may function as important triggers for daily-life ischaemia
by limiting coronary blood flow in the setting of increased
myocardial oxygen requirements.
One or several of these factors will determine the mech-
anism (in terms of increased myocardial oxygen demand
and reduced supply) responsible for an individual
ischaemic episode and the mechanisms are likely to
vary from patient to patient and ischaemic episode to
ischaemic episode. Clearly, increases in heart rate and
/7,-adrenergic activation are very important.
Calcium antagonist or /7-blocker for daily-life ischaemia?
/?-BLOCKERS
A large amount of data has been published from
controlled trials using /?-blockers for daily-life ischaemia.
1 n four reports using propranolol, a total of 153 patients
were studied'27"30'. The mean daily dose of propranolol
was just above 300 mg. Overall, there was about a 60%
reduction in the number and duration of ischaemic epi-
sodes. In two studies with metoprolol, the mean daily dose
was 400 mg and the reduction in the number and duration
of ischaemic episodes was about 8O%'31-32'. Compared
with propranolol (313mg mean), the metoprolol dose
was larger (400 mg mean) and the number of patients was
relatively small 19 metoprolol vs 153 propranolol.
In five studies with atenolol, a total of 72 patients were
reviewed and the average daily dose of atenolol was just
over 100 mg'33"37'. Treatment was associated with a reduc-
tion of about 64% in the number and a reduction of about
78% in the duration of ischaemic episodes. This dose is
lower than either the metoprolol or propranolol doses.
The results of these studies of /?-blockers were fairly con-
sistent so the results of over 200 patients were combined.
Average reductions in the number and duration of
ischaemic episodes were in the 60-80% range. There is
also a dose-response relationship; the studies which used
larger doses showed a greater decrease in daily-life
ischaemia.
CALCIUM ANTAGONISTS
In 11 controlled studies of the calcium antagonist,
nifedipine, which included 301 patients, the mean daily
Atenolol Propranolol Metoprolol Diltiazem Nifedipine
n Mean episodes (72%)





Figure 3 Comparison of /?-blockers and calcium antagonists in the
reduction in daily-life ischaemia.
dose of nifedipine was 64 mg'27-28-35-38"45'. The average
reduction in the number of ischaemic episodes was
39% and the average reduction in the duration of the
episodes was 43%, and there was no clear dose-response
relationship.
In five studies of the heart rate-specific calcium antag-
onist, diltiazem'27-30-37-41-461, a total of 149 patients received
a mean daily dose of 320 mg. There was a 48% reduc-
tion in the number and a reduction in the duration of
ischaemic episodes.
Experience with verapamil was limited to data from
only one small controlled trial'40'.
COMBINED RESULTS
The combined results of the /f-blocker and calcium
antagonist trials are summarized in Fig. 3. In the /?-
blocker trials there was an average reduction of about
70% in both the duration and number of ischaemic epi-
sodes, while in the calcium antagonist trials there was an
average reduction of about 40%. These data suggest,
therefore, that/?-blockers prevent a greater proportion of
daily-life ischaemic episodes than calcium antagonists.
One recently published study'271 on calcium antagonists
and/?-blockers compared the effect of placebo, diltiazem,
propranolol, and nifedipine in the same 50 patients. The
^-blocker eliminated the morning increase in heart rate
and reduced the rise in ischaemic episodes that began in
the morning hours. Nifedipine exaggerated the morning
increase in heart rate and it remained elevated throughout
the day. The response to diltiazem was intermediate
between propranolol and nifedipine. Thus, calcium
antagonists did not reduce daily-life ischaemia as much as
/?-blockers.
Several other recent studies compared responses to cal-
cium antagonists and /?-blockers in the same patients. In
studies by Deedwania et a/.'38' and Hill et a/.'35', atenolol
and nifedipine were compared. In another study by
Raymenants et a/.'37', atenolol and diltiazem were com-
pared. Analysis of these data revealed a highly significant
reduction in the incidence of daily-life ischaemia of about
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Figure 4 Comparison of /?-blockers and calcium antagonists in patients with daily-life





















Figure 5 The association of adverse events and persistent painless
ischaemia. Painless ischaemia was abolished by medical therapy in
12 patients and persistent in 22 patients. At follow up persistent
painless ischaemia was associated with a relative risk (RR) of adverse
events of 5-5. Adapted from Lim el a/.15'1.
40% by /J-blockers compared with calcium antagonists
(Fig. 4). Thus, these data suggest that the relative risk for
daily-life ischaemia is considerably less during treatment
with a /J-blocker compared with a calcium antagonist.
There are additional advantages to /J-blocker therapy.
Numerous epidemiological studies indicate that a low
heart rate is beneficial in patients with ischaemic heart
disease'47'48'. Other studies in animals suggest that low
heart rate is associated with less severe experimental cor-
onary atherosclerosis'4950'. Most myocardial infarctions
and episodes of ventricular tachycardia and ventricular
fibrillation which do not take place in hospital, occur in
the morning. They are reduced by /?-blockers. /?-blocker
activity coincides with ischaemic episodes and related
adverse events making them the most likely candidates to
influence outcome.
Unanswered questions
There are no controlled trial data to prove that treat-
ing patients for daily-life ischaemia improves outcome,
nor that suppression of ischaemia is associated with ben-
efits. In a recent pilot-type study, however, Lim et a/.'51'
described a small group of patients who had painless
exercise-induced ischaemia-related left ventricular wall
motion abnormalities. After 4 weeks of anti-ischaemic
pharmacotherapy, the patients were divided into two
groups based on another exercise wall motion (e.g. radio-
nuclide ventriculogram) study. In one group, treatment
abolished painless ischaemia, while in the other group,
painless ischaemia persisted despite therapy. After 9
months of follow-up, all but one of the adverse events
that occurred were in the group of patients in whom pain-
less ischaemia persisted (Fig. 5). Although this was a
small study of short duration (only 34 patients with a
brief, 9-month follow-up) the results support the hypothe-
sis that abolition of painless ischaemia is associated with
reduction of adverse outcome.
Trials in progress
There are five controlled trials currently underway or
recently completed (Table 3): Total Ischaemic Burden
European Trial (TIBET), Canadian Amlodipine Silent
Ischaemia Study (CAS1S), Atenolol Silent Ischaemia
Trial (ASIST), Asymptomatic Cardiology Ischaemia
Pilot (ACIP), and Angina Prognosis Study in Stockholm
(APSIS).
In TIBET over 600 patients were enrolled, but only
about one-third of the patients had daily-life ischaemia.
Three treatment strategies were examined; atenolol
monotherapy, nifedipine monotherapy, and atenolol-
nifedipine as combination therapy. The primary outcome
data will be published in the near future'52'.
In CASIS, 120 patients were randomized to either
amlodipine, atenolol, or a combination of these agents.
This study had a follow-up period of only 9 weeks and the
primary end-point was suppression of ischaemia. These
results will also be published in the near future.
In ASIST, the target sample size is 350 asymptomatic or
minimally symptomatic patients with evidence of CAD
and abnormal exercise tests who also have silent daily-life
ischaemia. The patients are randomized to receive either
atenolol or placebo and will be followed for 1 year.
Adverse outcome is the primary end-point. This study has
enrolled about 90% of patients needed and results should
be available in late 1993.
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Amlodipine vs atenolol vs combination
Placebo vs atenolol
Atenolol vs nifedipine vs combination
Symptom-guided care vs ischaemia-guided
care vs revascularization
Verapamil vs metoprolol
CASIS = Canadian Amlodipine Silent Ischemia Study
ASIST = Atenolol Silent Ischaemia Trial
TI BET = Total Ischaemic Burden European Trial
ACIP = Asymptomatic Cardiac Ischaemia Pilot
APSIS = Angina Prognosis Study In Stockholm
In the Swedish trial, APSIS, 790 patients are enrolled
and randomized to either metoprolol or verapamil. The
end-point is adverse outcome over 15 months.
ACIP has been initiated. A total of 618 patients with
CAD, abnormal exercise test response, and silent daily-
life ischaemia are randomized to one of the three treat-
ment strategies: angina-guided therapy, angina plus
ischaemia-guided therapy, and revascularization (e.g.
percutaneous transluminal coronary angioplasty or cor-
onary artery bypass graft). Within the two medical treat-
ment strategies, patients are also randomized to receive a
dose-titrated regimen of either atenolol plus nifedipine or
diltiazem plus isosorbide dinitrate, and will be followed
for 1 year which will end in December 1993. This study is a
pilot study for a major trial: the Asymptomatic Cardiac
Ischaemia Project (ACIP-II). This full scale trial would
involve 5000 patients and would examine the effect of
ischaemia treatment on mortality. The major trial could
begin as early as 1994 and could include centres in the
U.S.A., Canada, and Europe.
/?-BLOCKERS AND CALCIUM ANTAGONISTS IN COMBINATION
Some data suggest that there are advantages to the
combination of /?-blockers and calcium antagonists. The
pathophysiology of daily-life ischaemia includes both
increases in myocardial oxygen demand and limitations
and reductions in myocardial supply. Therefore, a combi-
nation of /?-blockers, which reduce myocardial oxygen
demand, and calcium antagonists, which improve myo-
cardial oxygen supply, should theoretically be advan-
tageous. Dargie et alP] examined the effects of combining
propranolol and nifedipine. This combination yielded a
greater reduction in daily-life ischaemic episodes than
either agent used as monotherapy. Hill et a/.'351 and
Raymenants et a/.'37' used combinations of atenolol plus
nifedipine and atenolol plus diltiazem; once again, the
combination appeared to be superior to monotherapy.
Likewise, in the study by Parmleye/a/.'44'the combination
of long-acting nifedipine with a y9-blocker provided
superior reduction in the number and duration of
ischaemic episodes. An additional advantage to combi-
nation therapy is that the doses can be reduced leading to
a reduction in side-effects.
Summary
Daily-life ischaemia, most of which is silent, has been
associated with increased risk for adverse outcome, fi-
blockers, which reduce heart rate and blood pressure and
have other important effects, also reduce or eliminate
daily-life ischaemia. Data from the published literature
indicate that /?-blocker therapy has a greater effect than
calcium antagonists in the suppression of daily-life
ischaemia when these agents are used as monotherapy.
Combination therapy with a /J-blocker and a calcium
antagonist appears to have distinct advantages over
monotherapy. Definitive data showing that treatment of
patients with daily-life ischaemia reduces adverse out-
come are lacking. Likewise, direct evidence supporting
the hypothesis that suppression of ischaemia is associated
with reduction in adverse outcome awaits the results of
large-scale clinical trials. There should be considerable
new information on this important problem in the next
few years.
References
[1] Pepine CJ. Ambulant myocardial ischaemia and its prognostic
implications. Circulation 1990:81: 1136-8.
[2] Pepine CJ. Is silent ischemia a treatable risk factor in
patients with angina pectoris? Circulation 1990; 82 (Suppl II):
II-135-II-142.
[3] Stern S, Tzivoni D. Early detection of silent ischaemic heart
disease by 24-hour electrocardiographic monitoring of active
subjects. Br Heart J 1974; 36: 481-6.
[4] DeWood MA, Rozanski A. Long term prognosis of patients
with and without silent ischemia (abstr). Circulation 1986; 74
(Supl II): 11-59.
[5] Rocco MB, Nabel EG, Campbell S, Goldman L. Prognostic
importance of myocardial ischemia detected by ambulatory
monitoring in patients with coronary disease. Circulation 1988;
78: 877-84.







fi-blockers or calcium antagonists in silent ischaemia? 13
[6] Von Arnim TH, Szeimies-Seebach U, Erath A, Schreiber MA,
Hofling B. Prognostic implications of ischaemia on ST-segment
monitoring. 4-5 year follow-up of 306 patients after coronary
angiography(abstr). Eur Heart J 1988; 9 (Abstract Suppl): P1464.
[7] Aronow WS, Epstein S. Usefulness of silent myocardial
ischemia detected by ambulatory electrocardiographic moni-
toring in predicting new coronary events in elderly patients. Am
JCardiol 1988; 62: 1295-6.
[8] Tzivoni D, Weisz G, Gavish A, Zin D, Keren A, Stern S.
Comparison of mortality and myocardial infarction rates in
stable angina pectoris with and without ischemic episodes
during daily activities. Am J Cardiol 1989; 63: 273-6.
[9] Deedwania PC, Carbajal EV. Silent ischemia during daily life
is an independent predictor of mortality in stable angina.
Circulation 1990; 81: 748-56.
[10] Johnson SM, Mauritson DR, Winniford MD, Willerson JT.
Continuous electrocardiographic monitoring in patients with
unstable angina pectoris: identification of high-risk subgroup
with severe coronary disease, variant angina, and/or impaired
early prognosis. Am Heart J 1982; 103:4-12.
[11] Pozzati A, Bugiardini R, Borghi A, Ottani F, Morgagni G,
Puddu P. Prognostic significance of mycoardial ischemia
refractory to maximal medical therapy in unstable angina
(abstr). Circulation 1988; 78 (Suppl II): 11-421.
[12] Von Arnim TH, Gerbig HW, Krawietz W, Hofling B.
Prognostic implications of transient — predominantly silent —
ischaemia in patients with unstable angina pectoris. Eur Heart J
1988; 9: 435-40.
[13] Gottlieb SO, Weisfeldt ML, Ouyang P, Mellits ED,
Gerstanblith G. Silent ischemia predicts infarction and death
during 2 year follow-up of unstable angina. J Am Coll Cardiol
1987; 10: 756-60.
[14] Nademanee K, Intarachot V, Josephson MA, Rieders D, Mody
FV, Singh BN. Prognostic significance of silent myocardial
ischemia in patients with unstable angina. J Am Coll Cardiol
1987; 10: 1-9.
[15] Langer A, Freeman MR, Armstrong PW. ST segment shift in
unstable angina: pathophysiology and association with coron-
ary anatomy and hospital outcome. J Am Coll Cardiol 1989; 13:
1495-502.
[16] Tzivoni D, Gavish A, Zin D, Gottlieb S, el al. Prognostic signifi-
cance ofischemic episodes in patients with previous myocardial
infarction. Am J Cardiol 1988; 62: 661-4.
[17] Gottlieb SO, Gottlieb SH, Achuff SC, Baumgardner R, ei al.
Silent ischemia on Holter monitoring predicts mortality in
high-risk postinfarction patients. JAMA 1988; 259: 1030-5.
[18] Gottlieb SO, Weisfeldt M L, Ouyang P, Mellits ED, Gerstenblith
G. Silent ischemia as a marker for early unfavorable outcomes in
patients with unstable angina. NEnglJMed 1986; 314: 1214-9.
[19] Mulcahy D, Cunningham D, Crean P, Wright C, el al.
Circadian variation of total ischaemic burden and its alteration
with anti-anginal agents. Lancet 1988; ii: 755-9.
[20] Yeung AC, Barry J, Orav J, Bonassin E, Raby KE, Selwyn AP.
Effects of asymptomatic ischemia on long-term prognosis in
chronic stable coronary disease. Circulation 1991; 83:
1598-604.
[21] Schang ST, Pepine CJ. Transient asymptomatic ST segment
depression during daily activity. Am J Cardiol 1977; 39:
396-402.
[22] Rozanski A, Bairey CN, Krantz DS, Friedman J, el al. Mental
stress and the induction of silent myocardial ischemia in
patients with coronary artery disease. N Engl J Med 1988; 318:
1005-12.
[23] Lambert CR, Coy K, Imperi G, Pepine CJ. Influence of beta-
adrenergic blockade defined by time series analysis on circadian
variation of heart rate and ambulatory myocardial ischemia.
Am J Cardiol 1989; 64: 835-9.
[24] Deedwania PC, Nelson JR. Pathophysiology of silent myocar-
dial ischemia during daily life: hemodynamic evaluation by sim-
ultaneous electrocardiographic and blood pressure monitoring.
Circulation 1990; 82: 1296-304.
[25] Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP.
Dilation of normal and constriction of atherosclerotic coronary
arteries caused by the cold pressor test. Circulation 1988; 77:
43-52.
[26] Selwyn AP, Ganz P. Myocardial ischemia in coronary disease.
N Engl J Med 1988; 318: 1058-60.
[27] Stone PH, Gibson RS, Glasser SP, DeWood MA, el al. ASIS
Study Group. Comparison of propranolol, diltiazem, and
nifedipine in the treatment of ambulatory ischemia in patients
with stable angina: differential effects on ambulatory ischemia,
exercise performance, and anginal symptoms. Circulation 1990;
82: 1962-72.
[28] Dargie HJ, Kynch PG, Krikler DM, Harris L, Krikler S.
Nifedipine and propranolol: a beneficial drug interaction. Am J
Med 1981; 71: 676-82.
[29] Khurmi NS, Bowles MJ, O-Hara MJ, Raftery EB. Effect of
propranolol on indices of intermittent myocardial ischemia,
assessed by exercise testing and ambulatory ST-segment
monitoring. Clin Cardiol 1986:9: 391-7.
[30] Khurmi NS, O'Hara MJ, Bowles MJ, Raftery EB. Effect of
diltiazem and propranolol on myocardial ischemia during
unrestricted daily life in patients with effort-induced chronic
stable angina pectoris. Eur J Clin Pharmacol 1987; 32:443-7.
[31] Willich SJS, Pohjola-Sintonen S, Bhatia SJS. Shook TL, el al.
Suppression of silent ischemia by metoprolol without alteration
of morning increase of platelet aggregability in patients with
stable coronary artery disease. Circulation 1989; 79: 557-65.
[32] Imperi GA, Lambert CR, Coy K, Lopez L, Pepine CJ. Effects
of titrated beta blockade (metoprolol) on silent myocardial
ischemia in ambulatory patients with coronary artery disease.
Am J Cardiol 1987; 60: 519-24.
[33] Quyyumi AA, Wright C, Mockus L, Fox KM. Effect of partial
agonist activity in y5-blockers in severe angina pectoris: a double
blind comparison of pindolol and atenolol. Br Med J 1984; 289:
951-3.
[34] Quyyumi AA, Crake T. Wright CM, Mockus LJ, Fox KM.
Medical treatment of patients with severe exertional and rest
angina: double blind comparison of /?-blockcr, calcium
antagonist, and nitrate. Br Heart J 1987; 57: 505-11.
[35] Hill JA, Gonzalez JI, Kolb R, Pepine CJ. Effects of atenolol
alone, nifedipine alone and their combination on ambulant
myocardial ischemia. Am J Cardiol 1991; 67: 671-5.
[36] Crea F, Pupita G, Galassi AR. El-Tamimi H. el al. Effects of
theophylline, atenolol and their combination on myocardial
ischemia in stable angina pectoris. Am J Cardiol 1990; 66:
1157-62.
[37] Raymenants E, Henson K. Kolb R, Boyette A, Hoffman C,
Pepine CJ. Value of very prolonged (120 hr) ambulatory ECG
monitoring for ambulatory myocardial ischemia. J Am Coll
Cardiol 1992; 19: 284A.
[38] Deedwania PC, Carbajal EV, Nelson J R, Hait H. Anti-ischemic
effects of atenolol versus nifedipine in patients with coronary
artery disease and ambulatory silent ischemia. J Am Coll
Cardiol 1991; 17:963-9.
[39] Crake T, Mulcahy D, Wright C. Fox KM. Labetalol in the
treatment of stable exertional angina pectoris: a comparison
with nifedipine. Eur Heart J 1988; 9: 1200-5.
[40] Subramanian VB, Bowles MJ, Khurmi NS. Davics AB, Raftery
EB. Rationale for the choice of calcium antagonists in chronic
stable angina. An objective double-blind, placebo-controlled
comparison of nifedipine and verapamil. Am J Cardiol 1982;
50:1173-9.
[41] FrishmanW.CharlapS. Kimmel B.Teicher M,elal. Diltiazem,
nifedipine, and their combination in patients with stable
angina pectoris: effects on angina, exercise tolerance, and the
ambulatory electrocardiographic ST segment. Circulation
1988; 77: 774-86.
[42] Von Arnim T, Erath A. Nitrates and calcium antagonists for
silent myocardial ischemia. Am J Cardiol 1988; 61: 15E-18E.
[43] Nesto RW, Phillips RT, Kelt KG, McAuliffe LS, Roberts M,
Hegarty P. Effect of nifedipine on total ischemic activity and
circadian distribution of myocardial ischemic episodes in
angina pectoris. Am J Cardiol 1991; 67: 128-32.
[44] Parmley WW, Nesto RW, Singh BN, Deanfield J, Gottlieb SO,
N-CAP Study Group. Attenuation of the circadian patterns of







14 C. J. Pepine
myocardial ischemia with nifedipine GITS in patients with
chronic stable angina. J Am Coll Cardio! 1992; 19: 1380-9.
[45] Shell WE, Dobson D. Dissociation of exercise tolerance and
total myocardial ischemic burden in chronic stable angina
pectoris. Am J Cardiol 1990; 66:42-8.
[46] Theroux P, Baird M, Juneau M, el al. Effect of diltiazem
on symptomatic and asymptomatic episodes of ST segment
depression occurring during daily life and during exercise.
Circulation 1991; 84: 15-22.
[47] Kjekshus J. Comments—Beta-blockers: Heart rate reduction a
mechanism of benefit. Eur Heart J 1985; 6 (Suppl A): 29-30.
[48] Kjekshus JK. Importance of heart rate in determining beta-
blocker efficacy in acute and long-term acute myocardial
infarction intervention trials. Am J Cardiol 1986; 57:43F-49F.
[49] Kaplin JR, Manuck SB, Adams MR, Weingand KW, Clarkson
TB. Inhibition of coronary atherosclerosis by propranolol in
behaviorally predisposed monkeys fed an atherogenic diet.
Circulation 1987; 76: 1364-72.
[50] Beere PA, Glagov S, Zarins CK. Retarding effect of lowered
heart rate on coronary atherosclerosis. Science 1984; 226:
180-2.
[51] Lim R, Dyke L, Dymond DS. Effect on prognosis of abolition
of exercise-induced painless myocardial ischemia by medical
therapy. Am J Cardiol 1992; 69: 733-5.
[52] TIBET Study Group. Total Ischaemic Burden Trial (TIBET):
Effect of treatment on exercise and Holter ECG in angina
(abstract). Circulation 1992; 86 (Suppl I): 1-713.
 by guest on O
ctober 7, 2016
http://eurheartj.oxfordjournals.org/
D
ow
nloaded from
 
